Search | Clinical Trials Finder

Conditions: Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: coagulation study, immunoenzyme technique, laboratory biomarker analysis, physiologic testing, study of high risk factors; Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Embolism, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions: Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis, Tissue Plasminogen Activator; Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prevention, Venous Thromboembolism
Interventions: Rivaroxaban (BAY59-7939), Enoxaparin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 2,457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Birmingham, Alabama • Denver, Colorado • Bay Pines, Florida + 2 more

Conditions: Acquired Hemophilia A
Interventions: OBIZUR; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Gainesville, Florida • Detroit, Michigan • Durham, North Carolina + 2 more

Conditions: Musculoskeletal Injury
Interventions: Fluoxetine, Calcium; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
Interventions: Radiofrequency Ablation (RFA), Chemotherapy; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Uterine Atony, Uterine Atony With Hemorrhage, Cesarean Section Complications
Interventions: Calcium Chloride, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
Interventions: Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT; Other · Drug
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years and older
Enrollment: 6,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 19 more

Conditions: Hemophilia A
Interventions: recombinant porcine coagulation factor VIII (OBI-1); Drug
Lead sponsor: Octagen Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Blue Bell, Pennsylvania

Conditions: Staphylococcal Infections
Interventions: SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, Blood sample, SA4Ag vaccine high dose, Placebo; Biological · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 16
States / cities: Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 10 more

Conditions: Factor X Deficiency
Interventions: FACTOR X; Biological
Lead sponsor: Bio Products Laboratory; Other
Eligibility: 12 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Coagulopathy
Interventions: Thromboelastography (TEG 6S); Diagnostic Test
Lead sponsor: Indiana University; Other
Eligibility: 3 Months to 18 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Severe Hemophilia A
Interventions: VWF/FVIII concentrates; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Duarte, California

Conditions: Osteoporosis, Prostate Cancer
Interventions: Calcium, Zoledronic acid, radiation therapy, LHRH, Vitamin D; Dietary Supplement · Radiation · Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 80
States / cities: Chico, California • Los Angeles, California • Pomona, California + 66 more

Conditions: Melanoma (Skin)
Interventions: NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure; Biological · Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Obstetric Hemostasis, Coagulation
Interventions: Quantra System; Diagnostic Test
Lead sponsor: HemoSonics LLC; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Gainesville, Florida • Raleigh, North Carolina • Winston-Salem, North Carolina

Conditions: Heart Disease, Lung Disease
Interventions: Thromboelastograph; Device
Lead sponsor: Stephen Esper; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hemophilia A, Hemophilia B
Interventions: fitusiran, factor concentrates; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 8
States / cities: Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more

Conditions: Osteogenesis Imperfecta
Interventions: Romosozumab, Calcium, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Indianapolis, Indiana • Nashville, Tennessee • Milwaukee, Wisconsin

Conditions: Multiple Sclerosis
Interventions: Blood sample collection for coagulation profile; Diagnostic Test
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Trauma Injury, Trauma, Coagulopathy
Interventions: Thromboelastography, Computational model; Diagnostic Test
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Uterine Fibroids, Uterine Myomas
Interventions: Halt Procedure; Device
Lead sponsor: Acessa Health, Inc.; Industry
Eligibility: 25 Years and older · Female only
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Pasadena, California + 6 more

Conditions: Hemophilia, Hemophilia A, Hemophilia B, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor, Haemophilia A Without Inhibitor, Haemophilia
Interventions: Not listed
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: 0 Years to 13 Years
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Phoenix, Arizona • Madera, California • San Diego, California + 24 more

Conditions: Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia, Cerebral Vasospasm, Autonomic Nervous System Diseases
Interventions: Right-Sided Cervical Sympathetic Block at C6, Transcutaneous Auricular Vagal Nerve Stimulation (taVNS); Procedure · Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery

Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Fluoxetine Mitigation Mental Health Study for Patients With Musculoskeletal Trauma

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

Calcium Chloride for Prevention of Uterine Atony During Cesarean

Platform of Randomized Adaptive Clinical Trials in Critical Illness

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery

Validation of Point-of-care Thromboelastography (TEG 6s) in Pediatric Patients

Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)

Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Reference Range Study for the Quantra System With the QStat Cartridge in Obstetric Patients

Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta

VALIDATE: Factor VIII Trending for MS Relapse

Trauma Induced Coagulopathy and Inflammation

Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

Noninvasive CA Monitoring Validation and Autonomic Modulation in Aneurysmal Subarachnoid Hemorrhage